GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
2022-01-04 $0.359 $0.360 $0.335 $0.342 376 259
2022-01-03 $0.346 $0.370 $0.335 $0.349 858 312
2021-12-31 $0.326 $0.344 $0.326 $0.333 671 598
2021-12-30 $0.327 $0.328 $0.315 $0.325 750 702
2021-12-29 $0.340 $0.340 $0.300 $0.328 1 211 944
2021-12-28 $0.340 $0.356 $0.333 $0.336 585 834
2021-12-27 $0.370 $0.378 $0.341 $0.344 1 331 610
2021-12-23 $0.362 $0.378 $0.360 $0.369 484 736
2021-12-22 $0.378 $0.378 $0.363 $0.367 803 190
2021-12-21 $0.378 $0.384 $0.366 $0.378 405 498
2021-12-20 $0.380 $0.385 $0.362 $0.378 753 194
2021-12-17 $0.370 $0.389 $0.370 $0.389 842 743
2021-12-16 $0.380 $0.397 $0.376 $0.380 1 911 803
2021-12-15 $0.416 $0.432 $0.401 $0.425 256 433
2021-12-14 $0.410 $0.446 $0.410 $0.421 349 686
2021-12-13 $0.450 $0.450 $0.414 $0.425 293 407
2021-12-10 $0.460 $0.482 $0.450 $0.454 200 680
2021-12-09 $0.474 $0.490 $0.442 $0.449 399 067
2021-12-08 $0.450 $0.498 $0.437 $0.480 288 554
2021-12-07 $0.411 $0.462 $0.411 $0.457 400 910
2021-12-06 $0.400 $0.427 $0.386 $0.424 619 098
2021-12-03 $0.440 $0.456 $0.410 $0.427 541 584
2021-12-02 $0.447 $0.460 $0.422 $0.435 773 004
2021-12-01 $0.480 $0.500 $0.440 $0.447 989 935
2021-11-30 $0.500 $0.510 $0.470 $0.480 516 157
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT